Cardiovascular risk prediction models for people with severe mental illness results from the prediction and management of cardiovascular risk in people with severe mental Illnesses (PRIMROSE) research program

JAMA Psychiatry

Volumn 72, Issue 2, 2015, Pages 143-151

  Osborn, David P J ^a,b   Hardoon, Sarah ^a   Omar, Rumana Z ^a   Holt, Richard I G ^c   King, Michael ^a,b   Larsen, John ^d   Marston, Louise ^a   Morris, Richard W ^a   Nazareth, Irwin ^a   Walters, Kate ^a   Petersen, Irene ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CAMDEN AND ISLINGTON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d RETHINK MENTAL ILLNESS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LITHIUM; NEUROLEPTIC AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ANGINA PECTORIS; ARTICLE; BIPOLAR DISORDER; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; PRESCRIPTION; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; SMOKING; SOCIAL ISOLATION; SYSTOLIC BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMORBIDITY; ELECTRONIC HEALTH RECORD; MIDDLE AGED; PROGNOSIS; PSYCHOTIC DISORDERS; RISK; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIPOLAR DISORDER; CARDIOVASCULAR DISEASES; COMORBIDITY; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; PSYCHOTIC DISORDERS; RISK; SCHIZOPHRENIA; UNITED KINGDOM;

EID: 84922212364     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.2133     Document Type: Article

References (27)

1. De HertM, Dekker JM,Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness: position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412-424.
2. Osborn DPJ, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry. 2007;64 (2):242-249.
3. Osborn DPJ,Wright CA, Levy G, King MB, Deo R, Nazareth I. Relative risk of diabetes, dyslipidaemia, hypertension and themetabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry. 2008;8: 84.
4. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
5. Mitchell AJ, Vancampfort D, De Herdt A, YuW, De HertM. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia a comparativemeta-analysis of first episode, untreated and treated patients. Schizophr Bull. 2013;39(2):295-305.
6. De HertM, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders, I: prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52-77.
7. Tiihonen J, Lönnqvist J,Wahlbeck K, et al. 11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627.
8. Crump C, WinklebyMA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170(3):324-333.
9. De HertM, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia a critical appraisal of the FIN-11 study. Schizophr Res. 2010;117(1):68-74.
10. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753.
11. National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care: NICE clinical guideline 82. London, United Kingdom: National Institute for Health and Clinical Excellence; 2009. http://www. nice. org. uk/CG082. Accessed November 17, 2014.
12. The Health Improvement Network home page. http://www. THIN-UK. com. Accessed January 18, 2014.
13. Davé S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiol Drug Saf. 2009;18 (8):704-707.
14. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19(4):251-255.
15. Lis Y, Mann RD. The VAMP Research multi-purpose database in the U. K. J Clin Epidemiol. 1995;48(3):431-443.
16. Horsfall L,Walters K, Petersen I. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol Drug Saf. 2013;22(1):64-69.
17. Fardet L, Petersen I, Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. BMJ. 2012;345:e4928. doi:10. 1136/bmj. e4928.
18. Horsfall LJ, Nazareth I, Petersen I. Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation. 2012;126(22):2556-2564.
19. Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ. 2009;339:b2584.
20. Quality and outcomes framework guidance for GMS contract 2011/12. http://www. nhsemployers org/PayAndContracts /GeneralMedicalServicesContract/QOF/Pages /ChangestoQOF2011-12. aspx. Accessed November 17, 2014.
21. Nazareth I, KingM, Haines A, Rangel L, Myers S. Accuracy of diagnosis of psychosis on general practice computer system. BMJ. 1993;307(6895): 32-34.
22. Uno H, Cai T, Pencina MJ, D'Agostino RB,Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011;30(10):1105-1117.
23. Royston P, SauerbreiW. A new measure of prognostic separation in survival data. Stat Med. 2004;23(5):723-748.
24. Hardoon S, Hayes JF, Blackburn R, et al. Recording of severe mental illness in United Kingdom primary care, 2000-2010. PLoS One. 2013;8(12):e82365. doi:10. 1371/journal. pone 0082365.
25. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J AmColl Cardiol. 2008;52(20):1628-1636.
26. Majeed A. Statins for primary prevention of cardiovascular disease. BMJ. 2014;348:g3491.
27. Hayward RA. Moneyball, gambling, and the new cholesterol guidelines. Circ Cardiovasc Qual Outcomes. 2014;7(2):311-314.